Skip to main content
SpringerLink
Log in

Why phase II trials in cervical chemoprevention are negative: what have we learned?

  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Cervical cancer is an important cause of mortality in women worldwide, and the cervix is a well-established clinical, cytologic, and histopathologic model of carcinogenesis. The cervix is easily accessible for examination and biopsy, and colposcopy improves visualization. Identifying chemopreventives in cervical cancer requires rigorous study design: dose de-escalating phase I, IIa trials; placebo-controlled phase IIb trials; and multicenter phase III trials. Reduction in disease incidence and surrogate endpoint biomarkers (SEB) may be trial endpoints. The goal of chemoprevention studies is to prevent or delay the development of cancer. Each agent requires a phase I or IIa trial for each organ site. Phase I, IIa studies of micronutrients, retinoids, α-difluoromethylornithine, and indole-3-carbinol have demonstrated response rates of up to 70%, but results of placebo-controlled phase IIb studies have been disappointing and their findings confounded by the high regression rates in placebo-treated patients. Enhancement of research methods, including sufficient enrollment guided by power calculations, uniform biopsy at study entry and exit, and strict progression through trial design phases would ensure valid and reliable results. Because human papillomavirus (HPV) is the major etiologic agent, pretrial laboratory and animal studies should have demonstrated the efficacy of the chemopreventive agent to decrease HPV viral protein expression or HPV tumor induction. SEB modulation must be characterized in any trial's earliest phases before use in phases IIb and III. Lessons learned in chemoprevention will serve as a basis for immunoprevention and vaccine trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827–841.

    Google Scholar 

  2. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H (1993) Trends in cancer incidence and mortality. IARC Sci Publ: 121: 1–806.

  3. American Cancer Society (2002) Cancer Facts & Figures 2002. Atlanta: American Cancer Society.

    Google Scholar 

  4. American Cancer Society (1995) Cancer Facts & Figures 1995. Atlanta: American Cancer Society.

    Google Scholar 

  5. Paavonen J, Koutsky LA, Kiviat N (1990) Cervical neoplasia and other STD-related genital-anal neoplasias. In: Holmes KK, Mardh PA, Sparling PF, Wiesner PJ, eds. Sexually Transmitted Diseases, 2nd edn. New York: McGraw-Hill, pp. 561–592.

    Google Scholar 

  6. US Department of Health and Human Services, Centers for Disease Control and Prevention (1999) The National Breast and Cervical Cancer Early Detection Program At-a-Glance 1999. Atlanta: Centers for Disease Control and Prevention.

    Google Scholar 

  7. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH (1994) Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 271: 1866–1869.

    Google Scholar 

  8. Ollayos CW, Swogger KA (1995) Abnormal cervical smears in the military recruit population. Mil Med 160: 577–578.

    Google Scholar 

  9. Center for Disease Control (1994) Results from the national breast and cervical cancer early detection program, October 31, 1991–September 30, 1993. Morb Mortal Wkly Rep 43: 530–534.

    Google Scholar 

  10. Romney SL, Dwyer A, Slagle S, et al. (1985) Chemoprevention of cervix cancer: phase I-II. A feasibility study involving the topical vaginal administration of retinyl acetate gel. Gynecol Oncol 20: 109–119.

    Google Scholar 

  11. Surwit EA, Graham V, Droegemueller W, et al. (1982) Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. Am J Obstet Gynecol 143: 821–823.

    Google Scholar 

  12. Meyskens FL Jr, Graham V, Chvapil M, et al. (1983) A phase I trial of b-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. J Natl Cancer Inst 71: 921–925.

    Google Scholar 

  13. Weiner SA, Surwit EA, Graham VE, et al. (1986) A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy. Invest New Drugs 4: 241–244.

    Google Scholar 

  14. Graham V, Surwit ES, Weiner S, Meyskens FL (1986) Phase II trial of b-ALL-trans-retinoic acid for cervical intraepithelial neoplasia via collagen sponge and cervical cap. West J Med 145: 192–195.

    Google Scholar 

  15. Meyskens FL Jr, Surwit E, Moon TE, et al. (1994) Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 86: 539–543.

    Google Scholar 

  16. Current Clinical Trials Oncology (2000) National Cancer Institute PDQ, Vol. 7, No. 1 (January-February) (protocol 13869).

  17. Follen M, Atkinson EA, Schottenfeld D, et al. (2001) A randomized clinical trial of 4–hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res 7: 3356–3365.

    Google Scholar 

  18. Romney SL, Basu J, Vermund S, Palan P, Duttagupta C (1987) Plasma reduced and total ascorbic acid in human uterine cervix dysplasias and cancer. Ann NY Acad Sci 498: 132–143.

    Google Scholar 

  19. Current Clinical Trials Oncology (1994) National Cancer Institute PDQ, Vol. 1, No. 2(March-April) (protocol 09315).

  20. Romney SL, Ho GYF, Palan PR, et al. (1997) Effects of bcarotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 65: 483–492.

    Google Scholar 

  21. Manetta A, Schubbert T, Chapman J, et al. (1996) b-Carotene treatment of cervical intraepithelial neoplasia: a phase II study. Cancer Epidemiol Biomarkers Prev 5: 929–932.

    Google Scholar 

  22. Current Clinical Trials Oncology (1994) National Cancer Institute PDQ, Vol. 1, No. 2 (March-April) (protocol 09088).

  23. Keefe KA, Schell MJ, Brewer C, et al. (1998) A randomized, double blind, phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 10: 1029–1035.

    Google Scholar 

  24. De Vet HCW, Knipschild PG, Willebrand D, Schouten HJA, Sturmans F (1991) The effect of beta-carotene on the regression and progression of cervical dysplasia: a clinical experiment. J Clin Epidemiol 44: 273–283.

    Google Scholar 

  25. Fairley CK, Tabrizi SN, Chen S, et al. (1996) A randomized clinical trial of beta carotene vs. placebo for the treatment of cervical HPV infection. Int J Gynecol Cancer 6: 225–230.

    Google Scholar 

  26. Mackerras D, Irwig L, Simpson JM, et al. (1999) Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities. Br J Cancer 79: 1448–1453.

    Google Scholar 

  27. Butterworth CE, Hatch KD, Soong SJ, et al. (1992) Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. Am J Obstet Gynecol 166: 803–809. Negative cervical chemoprevention trials 871

    Google Scholar 

  28. Butterworth CE Jr, Hatch KD, Macaluso M, et al. (1992) Folate deficiency and cervical dysplasia. JAMA 267: 528–533.

    Google Scholar 

  29. Childers JM, Chu J, Voigt LF, et al. (1995) Chemoprevention of cervical cancer with folic acid: a phase II Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev 4: 155–159.

    Google Scholar 

  30. Mitchell MF, Tortolero-Luna G, Lee JJ, et al. (1998) Phase I dose de-escalation trial of a-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res 4: 303–310.

    Google Scholar 

  31. Bell MC, Crowley-Nowick P, Bradlow HL, et al. (2000) Placebo controlled trial of indole-3–carbinol in the treatment of CIN. Gynecol Oncol 78: 123–129.

    Google Scholar 

  32. Kjaer SK (1998) Risk factors for cervical neoplasia in Denmark. APMIS (Suppl.) 80: 1–41.

    Google Scholar 

  33. Muñoz N, Bosch FX (1997) Cervical cancer and human papillomavirus: epidemiological evidence and perspectives for prevention. Salud Pu´blica de Me´xico 39: 274–282.

    Google Scholar 

  34. Muñoz N, Bosch FX (1992) HPV and cervical neoplasia: review of case-control and cohort studies. IARC Sci Publ 119: 251–261.

    Google Scholar 

  35. Bosch FX, Muñoz N, de Sanjose´ S, et al. (1993) Human papillomavirus and cervical intraepithelial neoplasia grade III/ carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 2: 415–422.

    Google Scholar 

  36. Bosch FX, Manos MM, Muñoz N, et al. (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796–802.

    Google Scholar 

  37. zur Hausen H (1999) Yohei Ito Memorial Lecture: Papillomaviruses in human cancers. Leukemia 13: 1–5.

    Google Scholar 

  38. Lowy DR, Schiller JT (1998) Papillomaviruses: prophylactic vaccine prospects. Biochim Biophys Acta 1423: M1–8.

    Google Scholar 

  39. Ostor G (1993) Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12: 186–192.

    Google Scholar 

  40. Mitchell MF, Hittelman WN, Hong WK, et al. (1994) The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. Cancer Epidemiol Biomarkers Prev 3: 619–626.

    Google Scholar 

  41. Mitchell MF, Tortolero-Luna G, Cook E, et al. (1998) A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for the treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 92: 737–744.

    Google Scholar 

  42. Boone CW, Kelloff GJ, Steele VE (1992) Natural history of intraepithelial neoplasia in humans with implications for cancer chemopreventive strategy. Cancer Res 52: 1651–1659.

    Google Scholar 

  43. Mitchell MF, Hittelman WK, Lotan R, et al. (1995) Chemoprevention trials in the cervix: design, feasibility, and recruitment. J Cell Biochem (Suppl.) 23: 104–112.

    Google Scholar 

  44. Goodman GE. The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and III objectives. Cancer Res 52 (9 Suppl.): 2752S-2757S.

  45. Begg C, Cho M, Eastwood S, et al. (1996) Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 276: 637–639.

    Google Scholar 

  46. Fahey MT, Irwig L, Macaskill P (1995) Meta-analysis of Pap test accuracy. Am J Epidemiol 141: 680–689.

    Google Scholar 

  47. Mitchell MF, Cantor SB, Ramanujam N, et al. (1999) Fluorescence spectroscopy for diagnosis of squamous intraepithelial lesions of the cervix. Obstet Gynecol 93: 462–470.

    Google Scholar 

  48. Mitchell MF, Cantor SB, Brookner C, et al. (1999) Screening for squamous intraepithelial lesions with fluorescence spectroscopy. Obstet Gynecol 94: 889–896.

    Google Scholar 

  49. Evans TRJ, Kaye SB (1999). Retinoids: present role and future potential. Br J Cancer 80: 1–8.

    Google Scholar 

  50. Lippman SM, Davies PJA (1997) Retinoids, neoplasia and differentiation therapy. Cancer Chemother Biol Response Mod 17: 349–362.

    Google Scholar 

  51. Delia D, Aiello A, Lombardi L, et al. (1993) N-(4–hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53: 6036–6041.

    Google Scholar 

  52. Bartsch D, Boye B, Baust C, zur Hausen H, Schwarz E (1992) Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO J 11: 2283–2291.

    Google Scholar 

  53. Batova A, Danielpour D, Pirisi L, Creek KE (1992) Retinoic acid induces secretion of latent transforming growth factor b1 and b2 in normal and human papillomavirus type 16–immortalized human keratinocytes. Cell Growth Differ 3: 763–772.

    Google Scholar 

  54. Woodworth CD, Notario V, DiPaolo JA (1990) Transforming growth factors a1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells. J Virol 64: 4767–4775.

    Google Scholar 

  55. Pietrantoni M, Taylor DD, Gercel-Taylor C, et al. (1995) The regulation of HPV oncogene expression by folic acid in cultured human cervical cells. J Soc Gynecol Invest 2: 228.

    Google Scholar 

  56. Ruffin MT, Bailey JM, Underwood D, et al. (1999) The potential use of HPV copy number and E6/E7 expression as biomarkers in cervical dysplasia. Proc Am Assoc Cancer Res 40 (abstract 2850).

  57. Ho GY, Burk RD, Klein S, et al. (1995) Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87: 1365–1371.

    Google Scholar 

  58. Comerci JT, Runowicz CD, Fields AL, et al. (1997) Induction of transforming growth factor a-1 in cervical intraepithelial neoplasia in vivo after treatment with b-carotene. Clin Cancer Res 3: 157–160.

    Google Scholar 

  59. Brewer CA, Wilczynski SP, Kurosaki T, Daood R, Berman ML (1997) Colposcopic regression patterns in high-grade cervical intraepithelial neoplasia. Obstet Gynecol 90: 617–621.

    Google Scholar 

  60. Butterworth CE Jr, Hatch KD, Macaluso M, et al. (1992) Folate deficiency and cervical dysplasia. JAMA 267: 528–533.

    Google Scholar 

  61. Auvinen M, Paasinen A, Andersson LC, Ho¨ ltta¨ E (1992) Ornithine decarboxylase activity is critical for cell transformation. Nature 360: 355–358.

    Google Scholar 

  62. Nishioka K, Melgarejo AB, Lyon RR, Mitchell MF (1995) Polyamines as biomarkers of cervical intraepithelial neoplasia. J Cell Biochem 23: 87–95.

    Google Scholar 

  63. Verma AK, Boutwell RK (1987) Inhibition of carcinogenesis by inhibitors of putrescine biosynthesis. In: McCann PP, Pegg AE, Sjoerdsma A, eds. Inhibition of Polyamine Metabolism, Biological Significance and Basis for New Therapies. Orlando: Academic Press, pp. 249–258.

    Google Scholar 

  64. Tempero MA, Nishioka K, Knott K, Zetterman RK (1989) Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. Cancer Res 49: 5793–5797.

    Google Scholar 

  65. Boiko IV, Mitchell MF, Pandey DK, et al. (1997) DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of a-difluoromethylornithine for cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 6: 849–855.

    Google Scholar 

  66. Bacus JW, Boone CW, Bacus JV, et al. (1999) Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials. Cancer Epidemiol Biomarkers Prev 8: 1087–1094. 872 M. Follen et al.

    Google Scholar 

  67. Hu W, Boiko IV, Mitchell MF, Hittelman WN, et al. (1995) Sequential dysregulation of proliferation during cervical carcinogenesis. Proc Am Assoc Cancer Res 36: (abstract 3500).

  68. Hu W, Mitchell MF, Boiko IV, et al. (1997) Progressive dysregulation of proliferation during cervical carcinogenesis as measured by MPM-2 antibody staining. Cancer Epidemiol Biomarkers Prev 6: 711–718.

    Google Scholar 

  69. Boiko IV, Mitchell MF, Hu W, et al. (1998) Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an a-difluoromethylornithine chemoprevention trial. Clin Cancer Res 4: 1383–1391.

    Google Scholar 

  70. Mitchell MF, Tortolero-Luna G, Lee JJ, et al. (1997) Polyamine measurements in the uterine cervix. J Cell Biochem Suppl 28–29: 125–132.

    Google Scholar 

  71. Chang YC, Riby J, Chang GH (1999) Cytostatic and antiestrogenic effects of 2–(indol-3–ylmethyl)-3,3¢-diindolylmethane, a major in vivo product of dietary indole-3–carbinol. Biochem Pharmacol 58: 825–834.

    Google Scholar 

  72. Cover CM, Hsieh S, Cram EJ, et al. (1999) Indole-3–carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 59: 1244–1251.

    Google Scholar 

  73. Katdare M, Osborne MP, Telang NT (1998) Inhibition of aberrant proliferation and induction of apoptosis in pre-neoplastic human mammary epithelial cells by natural phytochemicals. Oncol Rep 5: 311–315.

    Google Scholar 

  74. Cover CM, Hsieh SJ, Tran SH, et al. (1998) Indole-3–carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 273: 3838–3847.

    Google Scholar 

  75. Wong GY, Bradlow L, Sepkovic D, et al. (1997) Dose-ranging study of indole-3–carbinol for breast cancer prevention. J Cell Biochem Suppl 28–29: 111–116.

    Google Scholar 

  76. Jin L, Oi M, Chen DZ, et al. (1999) Indole-3–carbinol prevents cervical cancer in human papilloma virus type 16 (HPV 16) transgenic mice. Cancer Res 59: 3991–3997.

    Google Scholar 

  77. Follen M, Schottenfeld D(2001) Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials. Cancer 91: 1758–1776.

    Google Scholar 

  78. Stoler MH, Schiffman M (2001) Atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study (ALTS) group. JAMA 285: 2855–2856.

    Google Scholar 

  79. Follen M, Meyskens FL Jr, Atkinson EN, Schottenfeld D(2001) Why most randomized phase II cervical cancer chemoprevention trials are uninformative: lessons for the future. J Natl Cancer Inst 95: 1293–1296.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Gynecologic Oncology and Biomathematics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA

    Michele Follen, Anne-Thérèse Vlastos & E. Neely Atkinson

  2. Department of Gynecologic Oncology and Biomedical Engineering Center, The University of Texas M. D. Anderson Cancer Center, Box 193, 1515 M. D. Anderson Boulevard, Houston, TX, 77030, USA

    Michele Follen

  3. Chao Family Comprehensive Cancer Center, University of California–Irvine, Orange, California, 92868, USA

    Frank L. Meyskens Jr.

  4. Department of Epidemiology, University of Michigan, School of Public Health, Ann Arbor, Michigan, 48104, USA

    David Schottenfeld

Authors
  1. Michele Follen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne-Thérèse Vlastos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank L. Meyskens Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Neely Atkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Schottenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Follen, M., Vlastos, AT., Meyskens, F.L. et al. Why phase II trials in cervical chemoprevention are negative: what have we learned?. Cancer Causes Control 13, 855–873 (2002). https://doi.org/10.1023/A:1020660527600

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020660527600

Search

Navigation